KR20060132891A - 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도 - Google Patents
다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도 Download PDFInfo
- Publication number
- KR20060132891A KR20060132891A KR1020067015668A KR20067015668A KR20060132891A KR 20060132891 A KR20060132891 A KR 20060132891A KR 1020067015668 A KR1020067015668 A KR 1020067015668A KR 20067015668 A KR20067015668 A KR 20067015668A KR 20060132891 A KR20060132891 A KR 20060132891A
- Authority
- KR
- South Korea
- Prior art keywords
- formulation
- odv
- multiparticulate
- formate
- succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical class C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims abstract description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 230000002496 gastric effect Effects 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 66
- 238000009472 formulation Methods 0.000 claims description 62
- 238000000576 coating method Methods 0.000 claims description 37
- 239000011248 coating agent Substances 0.000 claims description 34
- ORUUBRMVQCKYHB-UHFFFAOYSA-N butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol Chemical compound OC(=O)CCC(O)=O.C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 ORUUBRMVQCKYHB-UHFFFAOYSA-N 0.000 claims description 30
- 239000008188 pellet Substances 0.000 claims description 20
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 18
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 18
- 229960004688 venlafaxine Drugs 0.000 claims description 17
- 239000001856 Ethyl cellulose Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 238000009505 enteric coating Methods 0.000 claims description 14
- 239000002702 enteric coating Substances 0.000 claims description 14
- 229920001249 ethyl cellulose Polymers 0.000 claims description 14
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- -1 hypomellose Polymers 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000013268 sustained release Methods 0.000 claims description 3
- 239000012730 sustained-release form Substances 0.000 claims description 3
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229960004981 desvenlafaxine succinate Drugs 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000011230 binding agent Substances 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 241000275031 Nica Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
- 229960001623 desvenlafaxine Drugs 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000001069 triethyl citrate Substances 0.000 description 3
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
- 235000013769 triethyl citrate Nutrition 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 150000004675 formic acid derivatives Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- SXDQRQUWNQKZBL-UHFFFAOYSA-N butanedioic acid;hydrate Chemical group O.OC(=O)CCC(O)=O SXDQRQUWNQKZBL-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54238404P | 2004-02-06 | 2004-02-06 | |
| US60/542,384 | 2004-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060132891A true KR20060132891A (ko) | 2006-12-22 |
Family
ID=34860300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020067015668A Withdrawn KR20060132891A (ko) | 2004-02-06 | 2005-01-25 | 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050175698A1 (https=) |
| EP (2) | EP2052717A1 (https=) |
| JP (1) | JP2007520553A (https=) |
| KR (1) | KR20060132891A (https=) |
| CN (1) | CN1917860A (https=) |
| AR (1) | AR050230A1 (https=) |
| AU (1) | AU2005212166A1 (https=) |
| BR (1) | BRPI0507372A (https=) |
| CA (1) | CA2554559A1 (https=) |
| CR (1) | CR8535A (https=) |
| EC (1) | ECSP066827A (https=) |
| IL (1) | IL177052A0 (https=) |
| NO (1) | NO20063963L (https=) |
| PA (1) | PA8622601A1 (https=) |
| PE (1) | PE20050771A1 (https=) |
| RU (1) | RU2006127437A (https=) |
| SG (1) | SG149894A1 (https=) |
| SV (1) | SV2005002008A (https=) |
| TW (1) | TW200528092A (https=) |
| WO (1) | WO2005077340A1 (https=) |
| ZA (1) | ZA200606526B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| PL350924A1 (en) * | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
| AU2002250058B2 (en) | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| US20080103171A1 (en) * | 2004-12-27 | 2008-05-01 | Astellas Pharma Inc. | Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof |
| DE602006010343D1 (de) * | 2005-03-31 | 2009-12-24 | Wyeth Corp | Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon |
| WO2007005961A2 (en) * | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| US7595340B2 (en) | 2005-07-15 | 2009-09-29 | Wyeth | Serotonin and norepinephrine reuptake inhibitor and uses thereof |
| US20070014859A1 (en) * | 2005-07-15 | 2007-01-18 | Wyeth | Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate |
| US20070015828A1 (en) * | 2005-07-15 | 2007-01-18 | Wyeth | Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof |
| US7687520B2 (en) | 2005-07-15 | 2010-03-30 | Wyeth Llc | Serotonin and norepinephrine reuptake inhibitors and uses thereof |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
| TR200909798T1 (tr) * | 2007-07-12 | 2010-05-21 | Dr. Reddy's Laboratories Ltd. | O-desmetilvenlafaksin. |
| CA2702664A1 (en) * | 2007-10-16 | 2009-04-23 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
| US20110046231A1 (en) * | 2007-10-22 | 2011-02-24 | Actavis Group Ptc Ehf | Solid forms of (±)-o-desmethylvenlafaxine salts |
| MX2012010659A (es) | 2010-03-31 | 2013-03-05 | Wockhardt Ltd | Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales. |
| KR20140030156A (ko) | 2011-04-12 | 2014-03-11 | 루핀 리미티드 | 방출-조절되는 데스벤라팍신 약학 조성물 |
| WO2013164559A1 (en) * | 2012-05-03 | 2013-11-07 | Cipla Limited | Antiretroviral composition |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3081496A (en) * | 1959-10-15 | 1963-03-19 | John F Moore | Method of forming flexible sheets of cured foamed rubber |
| AT294000B (de) * | 1965-01-11 | 1971-11-10 | Diersch & Schroeder | Verfahren zur Herstellung von Teppichen oder Läufern |
| US3885257A (en) * | 1972-10-30 | 1975-05-27 | Evans Ronald J P | Pressure controlled resilient supporting structure |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| US4603445A (en) * | 1983-09-09 | 1986-08-05 | Span-America Medical Systems, Inc. | Support pad and method of manufacture |
| US5099627A (en) * | 1990-09-28 | 1992-03-31 | Benjamin Obdyke Incorporated | Ventilated roof construction and method |
| US5203703A (en) * | 1991-08-27 | 1993-04-20 | Schneiderman Marc J | Deglutition training method and apparatus |
| US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US6162309A (en) * | 1998-04-21 | 2000-12-19 | Burlington Industries, Inc. | Reinforced foam backed carpet |
| US6197828B1 (en) * | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
| US6342533B1 (en) * | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
| PL350924A1 (en) * | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
| WO2000076955A1 (en) * | 1999-06-15 | 2000-12-21 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
| US6863972B2 (en) * | 2001-01-09 | 2005-03-08 | Crane Plastics Company Llc | Synthetic wood component having a foamed polymer backing |
| AU2002250058B2 (en) * | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| US20030152741A1 (en) * | 2002-02-05 | 2003-08-14 | Robbins Jeffrey L. | Patterned polyurethane foam and a process for the production of tufted goods with patterned foam backing |
| US20030190352A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon Bv | Compositions of venlafaxine base |
| AU2003247515A1 (en) | 2002-06-10 | 2003-12-22 | Wyeth | Novel formate salt of o-desmethyl-venlafaxine |
| JP2004359665A (ja) * | 2003-05-30 | 2004-12-24 | Rohm & Haas Co | 生体利用性増強剤を含有する治療組成物 |
-
2005
- 2005-01-25 AU AU2005212166A patent/AU2005212166A1/en not_active Abandoned
- 2005-01-25 SG SG200900798-0A patent/SG149894A1/en unknown
- 2005-01-25 CA CA002554559A patent/CA2554559A1/en not_active Abandoned
- 2005-01-25 KR KR1020067015668A patent/KR20060132891A/ko not_active Withdrawn
- 2005-01-25 US US11/042,436 patent/US20050175698A1/en not_active Abandoned
- 2005-01-25 BR BRPI0507372-3A patent/BRPI0507372A/pt not_active IP Right Cessation
- 2005-01-25 EP EP09002123A patent/EP2052717A1/en not_active Withdrawn
- 2005-01-25 CN CNA2005800042516A patent/CN1917860A/zh active Pending
- 2005-01-25 WO PCT/US2005/002215 patent/WO2005077340A1/en not_active Ceased
- 2005-01-25 RU RU2006127437/15A patent/RU2006127437A/ru not_active Application Discontinuation
- 2005-01-25 JP JP2006552145A patent/JP2007520553A/ja not_active Withdrawn
- 2005-01-25 AR ARP050100248A patent/AR050230A1/es unknown
- 2005-01-25 EP EP05711931A patent/EP1711167A1/en not_active Withdrawn
- 2005-01-27 TW TW094102533A patent/TW200528092A/zh unknown
- 2005-01-31 PE PE2005000114A patent/PE20050771A1/es not_active Application Discontinuation
- 2005-02-03 PA PA20058622601A patent/PA8622601A1/es unknown
- 2005-02-04 SV SV2005002008A patent/SV2005002008A/es not_active Application Discontinuation
-
2006
- 2006-07-24 IL IL177052A patent/IL177052A0/en unknown
- 2006-07-25 CR CR8535A patent/CR8535A/es not_active Application Discontinuation
- 2006-08-04 ZA ZA200606526A patent/ZA200606526B/xx unknown
- 2006-09-05 NO NO20063963A patent/NO20063963L/no not_active Application Discontinuation
- 2006-09-06 EC EC2006006827A patent/ECSP066827A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SV2005002008A (es) | 2005-11-04 |
| EP2052717A1 (en) | 2009-04-29 |
| JP2007520553A (ja) | 2007-07-26 |
| IL177052A0 (en) | 2006-12-10 |
| NO20063963L (no) | 2006-09-05 |
| CN1917860A (zh) | 2007-02-21 |
| ECSP066827A (es) | 2006-11-24 |
| PE20050771A1 (es) | 2005-11-15 |
| AR050230A1 (es) | 2006-10-11 |
| US20050175698A1 (en) | 2005-08-11 |
| RU2006127437A (ru) | 2008-03-20 |
| TW200528092A (en) | 2005-09-01 |
| SG149894A1 (en) | 2009-02-27 |
| WO2005077340A1 (en) | 2005-08-25 |
| AU2005212166A1 (en) | 2005-08-25 |
| PA8622601A1 (es) | 2005-10-28 |
| CA2554559A1 (en) | 2005-08-25 |
| EP1711167A1 (en) | 2006-10-18 |
| ZA200606526B (en) | 2010-03-31 |
| BRPI0507372A (pt) | 2007-07-10 |
| CR8535A (es) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101111230B (zh) | 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式 | |
| KR20060132891A (ko) | 다중미립자 ｏ－데스메틸벤라팍신 염 및 그의 용도 | |
| SK9899A3 (en) | Tramadol multiple unit formulations | |
| JP2009501233A (ja) | バイオアベイラビリティーの高いｏ−デスメチルベンラファキシンスクシネートの経口用遅延放出投薬形態 | |
| EP2405900A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP7325565B2 (ja) | ピリドスチグミンを含む持続放出組成物 | |
| TW200942273A (en) | Drug delivery systems comprising weakly basic drugs and organic acids | |
| EP2459180A1 (en) | Multi-layered, multiple unit pharmaceutical compositions | |
| CA2555295C (en) | Extended release coated mini-tablets of venlafaxine hydrochloride | |
| US20140023710A1 (en) | Milnacipran formulations | |
| JP2014101332A (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 | |
| MXPA06008933A (en) | Multiparticulate o-desmethylvenlafaxine salts and uses thereof | |
| US20140112995A1 (en) | Multi-layered, multiple unit pharmaceutical compositions | |
| KR20250110202A (ko) | 변형-방출 실로도신 조성물 및 남성 피임 방법에서 이의 용도 | |
| WO2023002004A1 (en) | Multiparticulate pharmaceutical composition | |
| AU2014246617A1 (en) | Multi-layered, multiple unit pharmaceutical compositions | |
| HK1091137B (en) | Extended release coated minitablets of venlafaxine hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20060802 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1202 | Submission of document of withdrawal before decision of registration |
Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment) Patent event code: PC12021R01D Patent event date: 20090806 |
|
| WITB | Written withdrawal of application |